Emicizumab for the treatment of haemophilia A: a narrative review.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
03
02
2019
accepted:
15
04
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
26
12
2019
Statut:
ppublish
Résumé
One of the most serious complications of the treatment of severe haemophilia A is the development of alloantibodies against exogenous factor VIII (FVIII). Inhibitors render factor replacement therapy ineffective, exposing patients to a remarkably high risk of morbidity and mortality. Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in newer haemostatic therapies that are not based on the replacement of the deficient FVIII. This review will focus on the most interesting among these innovative therapies, emicizumab, and will provide an update on its current stage of clinical development.
Identifiants
pubmed: 31246563
pii: 2019.0026-19
doi: 10.2450/2019.0026-19
pmc: PMC6596376
doi:
Substances chimiques
Antibodies, Bispecific
0
Antibodies, Monoclonal, Humanized
0
Blood Coagulation Factor Inhibitors
0
Isoantibodies
0
Recombinant Proteins
0
emicizumab
7NL2E3F6K3
F8 protein, human
839MOZ74GK
Factor VIII
9001-27-8
recombinant FVIIa
AC71R787OV
Factor VIIa
EC 3.4.21.21
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-228Références
J Thromb Haemost. 2018 Dec;16(12):2362-2374
pubmed: 30264916
Thromb Haemost. 2017 Jun 28;117(7):1348-1357
pubmed: 28451690
Blood Transfus. 2017 Sep;15(5):478-486
pubmed: 28686157
J Thromb Haemost. 2014 Feb;12(2):206-13
pubmed: 24738137
Blood. 2014 Nov 13;124(20):3165-71
pubmed: 25274508
Blood Transfus. 2017 May;15(3):281-282
pubmed: 28287380
Blood. 2017 Dec 7;130(23):2463-2468
pubmed: 29042366
N Engl J Med. 2018 Aug 30;379(9):811-822
pubmed: 30157389
Nat Med. 2012 Oct;18(10):1570-4
pubmed: 23023498
Expert Opin Drug Saf. 2018 Dec;17(12):1233-1237
pubmed: 30462521
Blood Transfus. 2018 Sep;16(5):457-461
pubmed: 29517971
Blood Transfus. 2013 Sep;11 Suppl 4:s77-81
pubmed: 24333317
Blood Transfus. 2013 Apr;11(2):178-82
pubmed: 22790275
Expert Rev Hematol. 2018 Nov;11(11):835-846
pubmed: 30278802
Lancet. 2016 Jul 9;388(10040):187-97
pubmed: 26897598
Blood Transfus. 2017 Oct;15(6):568-576
pubmed: 27893354
Blood Transfus. 2017 Jan;15(1):77-84
pubmed: 26674816
N Engl J Med. 2001 Jun 7;344(23):1773-9
pubmed: 11396445
Haemophilia. 2019 Jan;25(1):33-44
pubmed: 30427582
Clin Chem. 2019 Feb;65(2):254-262
pubmed: 30282700
Blood Transfus. 2018 Nov;16(6):535-544
pubmed: 29328905
Haemophilia. 2018 May;24(3):344-347
pubmed: 30070072
Hematology Am Soc Hematol Educ Program. 2015;2015:33-40
pubmed: 26637698
J Thromb Haemost. 2018 Jun;16(6):1078-1088
pubmed: 29645406
Ther Adv Hematol. 2018 Oct 10;9(10):319-334
pubmed: 30344994
Haemophilia. 2018 Jul;24(4):557-562
pubmed: 29808952
Blood Transfus. 2017 Jul;15(4):365-368
pubmed: 27483484
N Engl J Med. 2016 May 26;374(21):2044-53
pubmed: 27223146
Semin Thromb Hemost. 2016 Jul;42(5):526-32
pubmed: 27148843
Blood Transfus. 2018 Feb;16(2):215-220
pubmed: 28686156
Blood Rev. 2013 Jul;27(4):179-84
pubmed: 23815950
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):657-662
pubmed: 27913543
J Thromb Haemost. 2018 Jul;16(7):1383-1390
pubmed: 29734520
Haemophilia. 2019 Jan;25(1):11-20
pubmed: 30431213
Blood. 2016 Mar 31;127(13):1633-41
pubmed: 26626991
Blood Transfus. 2018 Nov;16(6):525-534
pubmed: 30201084
BioDrugs. 2018 Dec;32(6):561-570
pubmed: 30430367
N Engl J Med. 2017 Aug 31;377(9):809-818
pubmed: 28691557
Blood Transfus. 2017 May;15(3):285
pubmed: 28287386
Adv Clin Chem. 2019;88:151-167
pubmed: 30612605